Acute Myeloid Leukemia Clinical Trial
TCR Alpha/Beta and CD19-deplete Haplo-HSCT
This is an open label, interventional, non-randomized, phase II trial of TCR alpha/beta and CD19-depeleted allogeneic HCT in pediatric patients with hematologic disease.
This is a single-site, open label, interventional, non-randomized, phase II trial of TCRαβ/CD19 deplete allogeneic HCT as donor source and sole GVHD prophylaxis in pediatric patients with either malignant or non-malignant hematologic disease who are eligable for allogeneic HCT, but lack a HLA-matched sibling donor.
Age 31 days to <30 years
Have a malignant or non-malignant hematologic disease, defined as disease resulting from abnormal function of a cell of the hematopoietic stem cell lineage, that could benefit from an allogeneic HCT. Examples include acute and chronic leukemias, myelodysplastic syndrome, lymphoma, severe acquired and congenital cytopenias/marrow failure, white blood cell abnormalities, red blood cell abnormalities, and platelet abnormalities.
Clinical remission for patients with acute leukemia (MDS/AML excluded) or lymphoma
Lack a healthy and willing HLA-identical related donor, with the exception of patients with FA who will be eligible with a willing HLA-identical related donor given the standard use of T-cell depletion in matched sibling donor HCT in FA
Have a related or an unrelated donor who meets the donor selection criteria, is healthy, willing, and able to receive GCSF with or without Plerixafor, and undergo apheresis through placement of catheters in the antecubital veins or a temporary central venous catheter
Able to give informed consent if ≥ 18 years, or with legal guardian capable of giving informed consent if < 18 years
Provision of signed and dated informed consent form
Uncontrolled, active infection at time of HCT
Cardiac ejection fraction <45%
Creatinine clearance <60 mL/min/1.72 mL
Pulmonary diffusion capacity (adjusted for hemoglobin), FEV1, or FVC <60% of predicted or an O2 saturation <94% on room air if unable to perform pulmonary function testing
Serum ALT >5x upper limit of normal or bilirubin >2
Performance score (Lansky or Karnofsky) <50
Pregnant or lactating females, as many medications necessary for a successful HCT are potentially harmful to unborn babies and infants.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Aurora Colorado, 80045, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.